You just read:

Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Jul 31, 2019, 07:30 ET